Cancer Therapy

Biotech company confirms plans to produce Multiferon at Swedish facility

Published in Cancer Weekly, August 17th, 2004

Viragen (VRA) confirmed that its Swedish manufacturing facility in Ersboda is on schedule to begin production of Multiferon in September.

The company has been upgrading and expanding its production capabilities for its natural human alpha interferon drug. The company previously reported that it expects to report data later this year from studies evaluating Multiferon for the treatment of malignant melanoma.

Construction of the Ersboda facility was completed earlier this year and is currently undergoing validation required by the Swedish regulatory authorities.

Viragen is a biotechnology company specializing in the research,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-08-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry